Search

Your search keyword '"Biersack, Hans"' showing total 870 results
Start Over Author "Biersack, Hans"
870 results on '"Biersack, Hans"'

9. Nuclear Cardiology

Author

Assadi, Majid, Ahmadzadehfar, Hojjat, Biersack, Hans-Jürgen, Assadi, Majid, Ahmadzadehfar, Hojjat, and Biersack, Hans-Jürgen

Published
2018
Full Text
View/download PDF

12. Basic Sciences

Author

Assadi, Majid, Ahmadzadehfar, Hojjat, Biersack, Hans-Jürgen, Assadi, Majid, Ahmadzadehfar, Hojjat, and Biersack, Hans-Jürgen

Published
2018
Full Text
View/download PDF

21. Parathyroid Imaging

Author

Biersack, Hans-Jürgen, Heiden, Ursula, Bucerius, Jan, editor, Ahmadzadehfar, Hojjat, editor, and Biersack, Hans-Jürgen, editor

Published
2012
Full Text
View/download PDF

24. Tc-99m-labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types

Author

Altunay, Betuel, Goedicke, Andreas, Winz, Oliver H. H., Hertel, Fabian, von Mallek, Dirk, Meszaros, Levente K. K., Chand, Gitasha, Biersack, Hans-Juergen, Stickeler, Elmar, Krauss, Katja, Mottaghy, Felix M. M., Altunay, Betuel, Goedicke, Andreas, Winz, Oliver H. H., Hertel, Fabian, von Mallek, Dirk, Meszaros, Levente K. K., Chand, Gitasha, Biersack, Hans-Juergen, Stickeler, Elmar, Krauss, Katja, and Mottaghy, Felix M. M.

Abstract

The expression status of human epidermal growth factor receptor 2 (HER2) in cancer predicts response to HER2-targeted therapy. Therefore, its accurate determination is of utmost importance. In recent years, there has been an increase in research on noninvasive techniques for molecular imaging, as this method offers the advantages of a more accurate determination of HER2 status without the need for multiple biopsies. The technetium-labeled single-domain antibody RAD201, previously known as Tc-99m-NM-02, has been shown to be safe for use in breast cancer imaging with reasonable radiation doses, favorable biodistribution, and imaging characteristics. MethodsA total of six HER2-positive, heavily pretreated patients with different cancer types aged between 42 and 69 years (5 women and 1 man; the median age of 55.5) have been examined. In six of seven scans, the patients were administered 500 ml of Gelofusine (R) solution (40 mg/ml) for radiation protection before the tracer injection (434 & PLUSMN; 42 MBq). Planar scans were acquired with the patient supine at 10 min, 60 min, 160 min, 20 h, and 24 h after injection. A CT scan was acquired at 95 min, followed by local tomographic SPECT imaging. ResultsOne patient was scanned twice with RAD201, 3 months apart, resulting in a total of seven scans for six patients. Here, we show that the use of RAD201 in our patient group shows the same favorable biodistribution as in a previous study with RAD201 (NCT04040686) and that the radiation dose to the critical organ kidney can be reduced by the application of the plasma expander Gelofusine (R) by almost 50%. ConclusionRAD201 appears safe for use in humans and is a promising noninvasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment.

Published
2023

28. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry

Author

Hörsch, Dieter, Ezziddin, Samer, Haug, Alexander, Gratz, Klaus Friedrich, Dunkelmann, Simone, Krause, Bernd Joachim, Schümichen, Carl, Bengel, Frank M., Knapp, Wolfram H., Bartenstein, Peter, Biersack, Hans-Jürgen, Plöckinger, Ursula, Schwartz-Fuchs, Sabine, Baum, R. P., Baum, Richard P., editor, and Rösch, Frank, editor

Published
2013
Full Text
View/download PDF

42. 99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types.

Author

Altunay, Betül, Goedicke, Andreas, Winz, Oliver H., Hertel, Fabian, von Mallek, Dirk, Meszaros, Levente K., Chand, Gitasha, Biersack, Hans-Jürgen, Stickeler, Elmar, Krauss, Katja, and Mottaghy, Felix M.

Subjects
EPIDERMAL growth factor receptors, PROTEIN expression, SINGLE-photon emission computed tomography, MOLECULAR diagnosis, IMMUNOGLOBULINS
Abstract

The expression status of human epidermal growth factor receptor 2 (HER2) in cancer predicts response to HER2-targeted therapy. Therefore, its accurate determination is of utmost importance. In recent years, there has been an increase in research on noninvasive techniques for molecular imaging, as this method offers the advantages of a more accurate determination of HER2 status without the need for multiple biopsies. The technetium-labeled single-domain antibody RAD201, previously known as 99mTc-NM-02, has been shown to be safe for use in breast cancer imaging with reasonable radiation doses, favorable biodistribution, and imaging characteristics. Methods: A total of six HER2-positive, heavily pretreated patients with different cancer types aged between 42 and 69 years (5 women and 1 man; the median age of 55.5) have been examined. In six of seven scans, the patients were administered 500 ml of Gelofusine® solution (40 mg/ml) for radiation protection before the tracer injection (434 ± 42 MBq). Planar scans were acquired with the patient supine at 10 min, 60 min, 160 min, 20 h, and 24 h after injection. A CT scan was acquired at 95 min, followed by local tomographic SPECT imaging. Results: One patient was scanned twice with RAD201, 3 months apart, resulting in a total of seven scans for six patients. Here, we show that the use of RAD201 in our patient group shows the same favorable biodistribution as in a previous study with RAD201 (NCT04040686) and that the radiation dose to the critical organ kidney can be reduced by the application of the plasma expander Gelofusine® by almost 50%. Conclusion: RAD201 appears safe for use in humans and is a promising noninvasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE

Author

Sabet, Amir, Mader, Nicolai, Bittenbring, Jörg Thomas, Khreish, Fadi, Grünwald, Frank, Biersack, Hans-Jürgen, and Ezziddin, Samer

Subjects
peptide receptor radionuclide therapy, Communication, RS1-441, NET, Pharmacy and materia medica, peripheral blood stem cell collection, Medicine, ddc:610, PRRT, PBSC, neuroendocrine tumor, hematotoxicity
Abstract

Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since 177Lu-DOTATATE dose limitation may come from hematological rather than renal function, hematological peripheral blood stem cell backup might be desirable. Here, we report our initial experience of peripheral blood stem-cell collection (PBSC) in patients with treatment-related cytopenia and therefore high risk of bone-marrow failure. Five patients with diffuse bone-marrow infiltration of NET and relevant myelosuppression (≥grade 2) received PBSC before one PRRT cycle with 177Lu-DOTATATE (7.6 ± 0.8 GBq/cycle). Standard stem-cell mobilization with Granulocyte-colony stimulating factor (G-CSF) was applied, and successful PBSC was defined as a collection of >2 × 106/kg CD34+ cells. In case of initial failure, Plerixafor was administered in addition to G-CSF prior to apheresis. PBSC was successfully performed in all patients with no adverse events. Median cumulative activity was 44.8 GBq (range, 21.3–62.4). Three patients had been previously treated with PRRT, two of which needed the addition of Plerixafor for stem-cell mobilization. Only one of five patients required autologous peripheral blood stem-cell transplantation during the median follow up time of 28 months. PBSC collection seems to be feasible in NET with bone-marrow involvement and might be worth considering as a backup strategy prior to PRRT, in order to overcome dose-limiting bone-marrow toxicity.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results